MONITORING DEVICE FOR MANGEMENT OF INSULIN DELIVERY
    93.
    发明公开
    MONITORING DEVICE FOR MANGEMENT OF INSULIN DELIVERY 有权
    ÜBERWACHUNGSVORRICHTUNGZUR VERWALTUNG EINER INSULINABGABE

    公开(公告)号:EP2483824A1

    公开(公告)日:2012-08-08

    申请号:EP10763452.9

    申请日:2010-08-24

    IPC分类号: G06F19/00

    摘要: Monitoring system and method for use with diabetic treatment management. The system includes: a communication interface configured to permit access to stored raw log data, obtained over a certain time, being indicative of glucose measurements, meals consumed and insulin delivery; and a control unit including an unsupervised learning controller configured to receive and process said raw log data and determine at least one global insulin pump setting of basal rate, correction factor, carbohydrate ratio and insulin activity curve parameters. The system may include a processing unit including a first processor for processing measured data indicative of blood glucose level and generating first processed data, a second processor including at least one fuzzy logic module which receives input parameters corresponding to the measured data, the first processed data and a reference data, and processes the data to produce a qualitative output parameter to determine whether any treatment parameter should be modified.

    摘要翻译: 用于糖尿病治疗管理的监测系统和方法。 该系统包括:通信接口,被配置为允许访问在一定时间内获得的存储的原始日志数据,其指示葡萄糖测量值,膳食消耗量和胰岛素递送; 以及控制单元,其包括无监督学习控制器,其被配置为接收和处理所述原始对数数据并且确定基础速率,校正因子,碳水化合物比率和胰岛素活性曲线参数的至少一个全局胰岛素泵设置。 该系统可以包括处理单元,该处理单元包括第一处理器,用于处理指示血糖值的测量数据并产生第一处理数据;第二处理器,包括至少一个模糊逻辑模块,其接收对应于测量数据的输入参数,第一处理数据 和参考数据,并处理数据以产生定性输出参数,以确定是否应修改任何治疗参数。

    NITROGEN-CONTAINING OXYALKYLENE ESTERS AND USES THEREOF
    100.
    发明公开
    NITROGEN-CONTAINING OXYALKYLENE ESTERS AND USES THEREOF 失效
    含氮氧化烯酯及其用途

    公开(公告)号:EP0973389A1

    公开(公告)日:2000-01-26

    申请号:EP98911573.8

    申请日:1998-03-11

    摘要: This invention relates to compositions for and methods of treating, preventing or ameliorating cancer and other proliferative diseases as well as methods of inducing wound healing, treating cutaneous ulcers, treating gastrointestinal disorders, treating blood disorders such as anemias, immunomodulation, enhancing recombinant gene expression, treating insulin-dependent patients, treating cystic fibrosis patients, inhibiting telomerase activity, treating virus-associated tumors, especially EBV-associated tumors, modulating gene expression and particularly augmenting expession of tumor suppressor genes, inducing tolerance to antigens, treating, preventing or ameliorating protozoan infection or inhibiting histone deacetylase in cells. The compositions of the invention are to and the methods of the invention use nitrogen-containing oxyalkyl esters.